EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study

Angelique N Voorberg iD, Esmé Kamphuis iD, Wietske A Christoffers iD, Marie L A Schuttelaar iD

British Journal of Dermatology · 15.09.2023 · 189 (4) · 400-409

DOI: 10.1093/bjd/ljad156 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, online erschienen am 12.05.2023. Verfasst von Angelique N Voorberg und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Eczema, Dermatitis, Atopic. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi and Regeneron Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Effective treatment options for patients with chronic hand eczema (CHE) are scarce. Dupilumab is licensed for the treatment of moderate-to-severe atopic dermatitis and has shown promising results for the treatment of hand eczema in other studies.

Objectives

To evaluate the efficacy and safety of dupilumab in adult patients with severe CHE (subtypes recurrent vesicular hand eczema or chronic fissured hand eczema) who have an inadequate response/intolerance to alitretinoin, or when alitretinoin is medically inadvisable.

Methods

In this 16-week, randomized, double-blind, placebo-controlled proof-of-concept phase IIb trial, patients with severe CHE were randomized 2 : 1 to dupilumab 300 mg or placebo subcutaneously every 2 weeks. Patients visited the outpatient clinic at the initiation of the study drug, and every 4 weeks until 16 weeks of treatment. The primary endpoint was the proportion of patients achieving at least a 75% improvement on the Hand Eczema Severity Index score (HECSI-75) at week 16. Adverse events were monitored during each visit. The study was registered on ClinicalTrials.gov (identifier NCT04512339).

Results

In total, 30 patients were randomized, and 29 patients received the assigned study drug (dupilumab n = 20, placebo n = 9). At week 16, more patients achieved HECSI-75 in the dupilumab group than in the placebo group {95% [95% confidence interval (CI) 73.1–99.7] vs. 33% [95% CI 9.0–69.1]}. Dupilumab also showed greater least square mean percentage change from baseline to week 16 in peak pruritus Numerical Rating Scale compared with placebo [−66.5 ± 10.7 (95% CI −88.6 to −44.5) vs. −25.3 ± 17.0 (95% CI −60.1–9.4)]. Adverse events were similar for the dupilumab and placebo groups and were mostly mild. There were no serious adverse events, nor did any of the adverse events lead to discontinuation of the study drug.

Conclusions

Dupilumab was efficacious and well tolerated. Larger studies of longer duration are needed to provide more evidence on the ­efficacy of dupilumab in CHE. Moreover, larger studies could also enable comparisons between clinical subtypes or aetiological ­diagnoses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EczemaDermatitis, AtopicAdultHumansAlitretinoinAntibodies, Monoclonal, HumanizedTreatment OutcomeDouble-Blind MethodSeverity of Illness Index

Substanzen

dupilumabAlitretinoinAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Department of Dermatology, Isala Dermatologic Center, Zwolle, the Netherlands.

ORCID-Profile: Angelique N Voorberg, Esmé Kamphuis, Wietske A Christoffers, Marie L A Schuttelaar

Förderung

  • Sanofi and Regeneron Pharmaceuticals
  • Sanofi
  • Regeneron Pharmaceuticals
  • NIH

Zitieren

APA

Voorberg, A. N., Kamphuis, E., Christoffers, W. A., & Schuttelaar, M. L. A. (2023). Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study. British Journal of Dermatology, 189(4), 400-409. https://doi.org/10.1093/bjd/ljad156

Vancouver

Voorberg AN, Kamphuis E, Christoffers WA, Schuttelaar MLA. Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study. British Journal of Dermatology. 2023;189(4):400-409. doi:10.1093/bjd/ljad156

BibTeX
@article{Voorberg2023,
  author = {Voorberg, Angelique N and Kamphuis, Esmé and Christoffers, Wietske A and Schuttelaar, Marie L A},
  title = {Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study},
  journal = {British Journal of Dermatology},
  year = {2023},
  volume = {189},
  number = {4},
  pages = {400--409},
  doi = {10.1093/bjd/ljad156}
}
Kostenlos starten →